Supply Chain Disruptions Plague Von Willebrand Factor Treatment, ANMS Identifies Alternatives

For several months, a persistent supply shortage of WILFACTIN 100 UI/mL powder and solvent for injection, a human von Willebrand factor (vWF) concentrate, has been impacting patients and healthcare providers. This critical medication, essential for the treatment and prevention of bleeding episodes in individuals with von Willebrand disease (vWD), is facing availability challenges due to production issues at the manufacturing site of its laboratory, LFB. The Agence nationale de sécurité du médicament et des produits de santé (ANSM), France’s national drug safety agency, has acknowledged the situation and is actively guiding healthcare professionals toward alternative therapeutic solutions to ensure uninterrupted patient care.

The root cause of the current supply strain, as identified by the ANSM, lies in "a decrease in drug production due to the upgrading of certain equipment at the LFB manufacturing site." This technical necessity, while crucial for long-term production capacity and quality control, has created a temporary bottleneck, leading to reduced output of WILFACTIN. This situation is not unprecedented in the pharmaceutical industry, where complex manufacturing processes and specialized equipment often require periodic maintenance and upgrades. However, for a life-saving medication like vWF concentrate, such disruptions can have immediate and significant consequences for a vulnerable patient population.

Von Willebrand disease is the most common inherited bleeding disorder, affecting an estimated 1 in 1,000 to 1 in 10,000 people, depending on the severity and type of the disease. It is caused by a deficiency or defect in von Willebrand factor, a protein crucial for blood clotting. This protein plays a dual role: it facilitates the adhesion of platelets to the site of injury and acts as a carrier for Factor VIII, another essential clotting protein. Individuals with vWD can experience a range of bleeding symptoms, from mild bruising and nosebleeds to severe gastrointestinal or joint hemorrhages, particularly during surgery or trauma.

WILFACTIN, a plasma-derived concentrate, is a cornerstone therapy for many patients with vWD. Its primary indication is for the treatment and prevention of hemorrhages and in surgical situations for patients with von Willebrand disease when treatment solely with desmopressin (DDAVP) is ineffective or contraindicated. Desmopressin is a synthetic hormone that can stimulate the release of vWF and Factor VIII from storage sites in the body, but its effectiveness varies, and it is not suitable for all types of vWD or all patients. WILFACTIN can be used across all age groups and is specifically designed to address the needs of those for whom desmopressin is not a viable option. Importantly, it is not indicated for the treatment of Hemophilia A, a separate but related bleeding disorder.

The current supply challenges have necessitated a proactive approach from the ANSM. To maintain the continuity of patient care, the agency has provided clear guidance to healthcare professionals regarding available therapeutic alternatives. This guidance is the result of close collaboration with key stakeholders in the rare disease community.

Collaborative Effort to Identify Alternative Treatments

The ANSM’s response has been developed in consultation with the MHEMO (Maladies Hémorragiques Rares) alliance, a prominent French organization representing patients and professionals involved in rare hemostasis disorders. MHEMO brings together reference centers for coagulation disorders and the Permedes network, a platform dedicated to the exchange and research on blood-derived medicines and recombinant analogs. This collaborative approach ensures that the identified alternatives are not only clinically appropriate but also address the practical realities faced by specialized treatment centers.

To facilitate informed decision-making by clinicians, the ANSM has compiled a comprehensive table outlining alternative therapeutic solutions. This table considers various factors, likely including the specific type and severity of von Willebrand disease, patient age, co-existing medical conditions, and the availability of alternative products. While the specific details of the ANSM’s table are not fully enumerated in the provided text, the core message is clear: a range of comparable treatments exists.

Key Therapeutic Alternatives Identified

The ANSM has specifically highlighted three main therapeutic categories or products that can be utilized as alternatives to WILFACTIN. These alternatives generally fall into categories of von Willebrand factor concentrates that may also contain Factor VIII. The specific products mentioned are:

• VONCENTO: This is a vWF/FVIII concentrate.
• EQWILATE: Similar to VONCENTO, EQWILATE is a vWF/FVIII concentrate.
• OCTAPLASLG: This is a solvent-detergent treated plasma product that can also provide vWF and FVIII.

The ANSM emphasizes that "alternative therapeutic solutions are available in sufficient quantities to allow the continuation of treatment for patients who can benefit from them." This assurance is critical for alleviating anxiety among patients and healthcare providers.

Important Considerations for Alternative Treatments

While these alternatives offer a viable path forward, the ANSM also provides crucial cautionary advice for their use. When using von Willebrand factor concentrates that also contain Factor VIII, such as EQWILATE or VONCENTO, for repeated injections, close monitoring of Factor VIII concentrations in the blood is essential. Elevated levels of Factor VIII, particularly exceeding 150 UI/dL, can increase the risk of thrombosis, a serious condition involving blood clot formation. This underscores the need for careful clinical management and vigilant patient observation when switching therapies.

The ANSM strongly advises physicians to "contact the reference center for von Willebrand disease (CRMW) to discuss specific clinical situations that may limit the use of alternatives." This recommendation highlights the complexity of managing bleeding disorders and the importance of personalized treatment strategies. Reference centers, with their specialized expertise and experience, can offer invaluable guidance on selecting the most appropriate alternative for individual patients, considering their unique medical history and potential risks.

Timeline of Supply Concerns and Agency Response

The supply issues with WILFACTIN have been ongoing for "several months," with the current article referencing a previous report from March 17, 2026, indicating that the problem was already well-established by that date. This suggests a prolonged period of reduced availability, potentially beginning in late 2025 or early 2026. The ANSM’s detailed guidance and identification of alternatives, as presented in this article, represent a significant step in managing the crisis, likely occurring in recent weeks or months as the supply situation continued to evolve. The agency’s proactive stance and collaborative efforts with patient groups and medical professionals demonstrate a commitment to patient safety and treatment continuity.

Broader Implications of Pharmaceutical Supply Chain Vulnerabilities

This situation with WILFACTIN serves as a stark reminder of the fragility of global pharmaceutical supply chains. The reliance on specialized manufacturing facilities and complex production processes means that even minor disruptions can have far-reaching consequences. For rare disease medications, where patient populations are smaller and the development of new treatments can be challenging, supply continuity is paramount.

The event highlights several key implications:

• Importance of Diversification: The reliance on a single manufacturing site for a critical medication underscores the potential benefits of supply chain diversification. While challenging and costly, having multiple production facilities or ensuring robust contingency plans can mitigate the impact of localized disruptions.
• Need for Enhanced Transparency and Communication: Proactive and transparent communication from manufacturers and regulatory bodies is vital during supply shortages. This allows healthcare providers and patients to prepare, adapt, and make informed decisions. The ANSM’s detailed guidance in this instance is a positive example of such communication.
• Value of Collaborative Networks: The successful identification of alternatives through collaboration with patient advocacy groups like MHEMO and specialized centers like CRMW demonstrates the critical role of these networks in navigating pharmaceutical crises. They provide essential expertise, patient insights, and a platform for coordinated action.
• Investment in Manufacturing Infrastructure: The ANSM’s explanation points to necessary upgrades of manufacturing equipment. While essential for quality, these upgrades can temporarily impact supply. This suggests a need for careful planning and communication around such maintenance periods, perhaps involving phased upgrades or buffer stock management.

The ongoing shortages of WILFACTIN, while concerning, are being addressed through a structured and collaborative approach. The ANSM’s commitment to guiding healthcare professionals toward viable alternatives, coupled with the engagement of key patient and medical organizations, offers reassurance that efforts are being made to minimize the impact on patients with von Willebrand disease. However, the situation also serves as a catalyst for continued dialogue and action to strengthen the resilience of pharmaceutical supply chains for essential medicines.